Sign In
Buy C
$135.13
+5.14 (+3.95%)
At Close: Jun 04, 2026
US Bank Stocks Tumble as Sweeping Tariff Stokes Recession Fears
10:46am, Friday, 04'th Apr 2025
Shares of C, BAC, MS, GS and WFC took a heavy hit on Thursday's trading session after Trump announced sweeping tariffs, raising recession risks.
Citigroup Declares Common Stock Dividend
08:01pm, Thursday, 03'rd Apr 2025
NEW YORK--(BUSINESS WIRE)--The Board of Directors of Citigroup Inc. today declared a quarterly dividend on Citigroup's common stock of $0.56 per share, payable on May 23, 2025, to stockholders of reco
Citigroup Announces $3.5 Billion Redemption of 3.106% Fixed Rate/Floating Rate Notes Due 2026
04:15pm, Thursday, 03'rd Apr 2025
NEW YORK--(BUSINESS WIRE)--Citigroup Inc. is announcing the redemption, in whole, constituting $3,500,000,000 of its 3.106% Fixed Rate / Floating Rate Notes due 2026 (the “notes”) (ISIN: US172967M
Citigroup Is Still A Mess: But Maybe That's The Opportunity
03:30pm, Thursday, 03'rd Apr 2025
Citigroup is undervalued, trading at 0.79x tangible book value, presenting a potential long-term investment if Jane Fraser's restructuring plan succeeds. Despite weak sentiment and regulatory issues,
Here's Why Bank Stocks Are Getting Crushed by Tariffs
02:33pm, Thursday, 03'rd Apr 2025
The stock market was having its worst day in years on Thursday after President Trump announced tariffs on more than 180 countries that were far worse than expected. As of 1 p.m.
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
04:05pm, Wednesday, 02'nd Apr 2025
FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
04:56pm, Tuesday, 01'st Apr 2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunot
Citigroup: A Stable And Consistent Financial Stock For Every Portfolio
08:51am, Tuesday, 01'st Apr 2025
Citigroup's (C) cost-cutting measures, technology modernization, and strategic exits have led to tangible improvements, positioning it as a "buy" despite macroeconomic challenges. C's strong CET1 and
Citigroup (C) Outperforms Broader Market: What You Need to Know
06:50pm, Monday, 31'st Mar 2025
In the most recent trading session, Citigroup (C) closed at $70.99, indicating a +0.94% shift from the previous trading day.
Former Citi CEO Sandy Weill launches new cancer research hub focused on immunotherapy
07:35am, Thursday, 27'th Mar 2025
Sandy Weill on Thursday announced a new $50 million donation to create a cancer research and treatment hub focused on immunotherapy. The hub is in partnership with four leading research institutions.
Citigroup (C) Could Be a Great Choice
12:45pm, Wednesday, 26'th Mar 2025
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Citigroup (C) have what it takes?
Why Citigroup (C) Outpaced the Stock Market Today
06:56pm, Tuesday, 25'th Mar 2025
In the latest trading session, Citigroup (C) closed at $74.47, marking a +0.58% move from the previous day.
These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Monday, 24'th Mar 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Citigroup Stock Has Lost 16% in the Market Sell-Off. Is It a Buy?
05:30am, Sunday, 23'rd Mar 2025
The S&P 500 index (^GSPC 0.08%) quickly fell into correction territory not too long ago. Dropping alongside the index were the shares of Citigroup (C 0.17%).
Investors Heavily Search Citigroup Inc. (C): Here is What You Need to Know
05:45pm, Friday, 21'st Mar 2025
Citigroup (C) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
